List of Oncology Medication For

Immunotherapy

EPKINLY (epcoritamab-bysp) injection

EPKINLY (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data.

Brand Name:	EPKINLY
Generic Name:	epcoritamab-bysp
Strength:	• Injection: 4 mg/0.8 mL in a single-dose vial. Dilute prior to use. • Injection: 48 mg/0.8 mL in a single-dose vial.
Manufacturer:	Genmab US, Inc.
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “EPKINLY (epcoritamab-bysp) injection” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for EPKINLY (epcoritamab-bysp) injection price list or cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

EPKINLY (epcoritamab-bysp) injection

Lymphoma, Immunotherapy

Brand Name: EPKINLY Generic Name: (epcoritamab-bysp). EPKINLY (epcoritamab-bysp) is used to treat lymphoma.

Epcoritamab-bysp is approved to treat adults with: Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma. Follicular lymphoma.

Brand Name:	EPKINLY
Generic Name:	epcoritamab-bysp
Strength:	• Injection: 4 mg/0.8 mL in a single-dose vial. Dilute prior to use. • Injection: 48 mg/0.8 mL in a single-dose vial.
Manufacturer:	Genmab US, Inc
Approved By:	EMA, USFDA

Source Details: Patient Information

IPN, New Delhi can facilitate patient to import of “EPKINLY (epcoritamab-bysp)” in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please email IPN healthcare Support Team for EPKINLY (epcoritamab-bysp) cost in India. on Mr. Tarun:- +91 9891 296 838 / Mr. Neeraj:- +91 9811 747 774.

Furmonertinib Tablets

Immunotherapy, Lung Cancer

Treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR T790M and other sensitizing mutations.

Brand Name:	Furmonertinib Tablets
Generic Name:	Furmonertinib Tablets
Strength:	• Oral Tablets: 40 mg x 28 tablets/box
Manufacturer:
Approved By:	NMPA

Source Details: Patient Information

Access Furmonertinib for NSCLC on a Named Patient Import Basis

IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to Furmonertinib Tabletsn for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).

For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.

Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.

HERNEXEOS (zongertinib tablets)

Lung Cancer, Immunotherapy

Sacituzumab tirumotecan Injection

Immunotherapy

Sacituzumab Tirumotecan is FDA-approved for the treatment of metastatic triple-negative breast cancer (TNBC) in patients who have already undergone at least two prior therapies, including chemotherapy. Additionally, Sacituzumab FDA approved for the treatment of metastatic urothelial carcinoma in patients who have previously received platinum-based chemotherapy and immune checkpoint inhibitors.

Sacituzumab tirumotecan must always be used under the supervision of a Registered Medical Practitioner (RMP).

Access Sacituzumab tirumotecan for TNBC on a Named Patient Import Basis

IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to Sacituzumab tirumotecan Injection for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).

Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.

ZEGFROVY (sunvozertinib) tablets

Immunotherapy, Lung Cancer

Zegfrovy (sunvozertinib) is an oral, third-generation EGFR-TKI used to treat adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

REZDIFFRA must always be used under the supervision of a Registered Medical Practitioner (RMP).

Access ZEGFROVY for NSCLC on a Named Patient Import Basis

IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to ZEGFROVY (sunvozertinib) tablets for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).

Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.

Contact Info

CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398

EMAIL ID:
info@indianpharmanetwork.co.in

FAX NUMBER:
+91-11-26532129

Query Form For Medications

Note

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Disclaimer

“Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in is intended to provide general information about consultancy services offered by IPN and to help users access this information in a user friendly format. Certain information available on the website has been sourced from publicly available sources. While Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in believes such information to be reasonably accurate, Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in has not independently verified any of this information. All information on the IPN website is of general nature and is not a substitute for medical prescription. None of the medicines or products mentioned on the IPN website are manufactured or sold by IPN Pharma Network.

Privacy Policy

Please read the following statement to learn about our information gathering and dissemination practices in relation to our consultancy services (“Services”). Note: Our privacy policy is subject to change at any time without notice. To make sure you are aware of any changes, please review this policy periodically. By visiting the Indian Pharma Network

Health Information

“All information available on the Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in is of general nature and is not a substitute for professional medical advice by a licensed practitioner. Indian Pharma Network (IPN) does not purport to provide any medical or health-related advice, even of general nature and therefore you should not use or consult the Indian Pharma Network (IPN) website www.indianpharmanetwork.co.in for any questions in relation to your health or medical condition.

Shipped Anti-Cancer Medicines.

Indian Pharma Network is registered medical pharmacy for Oncology Products in India. Helps you to access FDA approved Anti-Cancer-Medicines, no matter where you live. Sourcing each medicine for named patient use and overseeing every aspect of the shipping, customs and delivery. We have helped more than 6,000 patients. Send your enquiry to find the What is the cost of Anti Cancer Medicines in Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India.

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network

60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398

Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in

Immunotherapy

EPKINLY (epcoritamab-bysp) injection

EPKINLY (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023

EPKINLY (epcoritamab-bysp) injection

Brand Name: EPKINLY Generic Name: (epcoritamab-bysp). EPKINLY (epcoritamab-bysp) is used to treat lymphoma.

Furmonertinib Tablets

Access Furmonertinib for NSCLC on a Named Patient Import Basis

HERNEXEOS (zongertinib tablets)

Sacituzumab tirumotecan Injection

Access Sacituzumab tirumotecan for TNBC on a Named Patient Import Basis

ZEGFROVY (sunvozertinib) tablets

Access ZEGFROVY for NSCLC on a Named Patient Import Basis

Contact Info

Query Form For Medications

Note

Disclaimer

Privacy Policy

Health Information

Shipped Anti-Cancer Medicines.

Indian Pharma Network (IPN), New Delhi. India

Company

Drugs Approved for

Gastroenterology

Hematology

Drugs Approved For